Keywords
molecular docking
Alzheimer’s disease
FlexX
ZINC database
Abstract
While Alzheimer disease is the most common form of dementia, acetylcholinesterase is an interesting therapeutic target for the development of new anti-Alzheimer’s disease drugs. In order to discover potential compounds inhibiting this protein target, a molecular docking study of a similar collection of 1-[[2,4-bis[(E)hydroxyiminomethyl] pyridin-1-ium-1-yl]methoxymethyl] pyridin-1-ium-4-carboxamide (HLO) inhibitor from ZINC database using FlexX program was realized. Before performing the molecular docking, FlexX was validated by Root mean square deviation test to determine the reproducibility of the docking program. The strategy undertaken in this study permitted us to propose products 4-[[2-[(Z)-N’-hydroxycarbamimidoyl]-4-pyridyl]methylamino] benzamide and N-[(E)-[1-(4-nitrophenyl)pyrrol-2-yl]methylene amino]isonicotinamide as potential new inhibitors of humane acetylcholinesterase. The two proposed products may act as strong anti-Alzheimer leads compounds.References
1. Atlee JL. Complications in Aanesthesia. Philadelphia: Saunders Elsevier; 2007.
2. Burns A, Iliffe S. Alzheimer’s disease. BMJ. 2009;338:b158.
3. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J. 1978;2(6150):1457-9.
4. Perry EK, Walker M, Grace J, Perry RH. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999; 22(6):273-80.
5. Draczkowski P, Tomaszuk A, Halczuk P, Strzemski M, Matosiuk D, Jozwiak K. Determination of affinity and efficacy of acetylcholinesterase inhibitors using isothermal titration calorimetry. Biochim Biophys Acta Gen Subj. 2016;1860(5):967-74.
6. Dhanjal JK, Sharma S, Grover A, Das A. Use of ligand-based pharmacophore modeling and docking approach to find novel acetylcholinesterase inhibitors for treating Alzheimer’s. Biomed Pharmacother. 2015;71:146-52.
7. Chigurupati S, Selvaraj M, Mani V, Selvarajan KK, Mohammad JI, Kaveti B, et al. Identification of novel acetylcholinesterase inhibitors: indolopyrazoline derivatives and molecular docking studies. Bioorg Chem. 2016;67:9-17.
8. Lane RM, Kivipelto M, Greig NH. Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol. 2004;27:141-9.
9. Galisteo M, Rissel M, Sergent O, Chevanne M, Cillard J, Guillouzo A, et al. Hepatotoxicity of tacrine: occurrence of membrane fluidity alterations without involvement of lipid peroxidation. J Pharmacol Exp Ther. 2000;294:160-7.
10. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Db Syst Rev. 2006;1:CD005593.
11. Alldredge KB. Applied therapeutics: The clinical use of drugs. 10th ed. Baltimore: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013.
12. Chitranshi N, Gupta S, Tripathi PK, Seth PK. New molecular scaffolds for the design of Alzheimer's acetylcholinesterase inhibitors identified using ligand- and receptor-based virtual screening. Med Chem Res. 2013;2:2328-45.
13. Quinn DM. Acetylcholinesterase: Enzyme structure, reaction dynamics, and virtual transition states. Chem Rev. 1987;87:955-75.
14. Szegletes T, Mallender WD, Thomas PJ, Rosenberry TL. Substrate binding to the peripheral site of acetylcholinesterase initiates enzymatic catalysis. Substrate inhibition arises as a secondary effect. Biochemistry. 1999;38:122-33.
15. Bourne Y, Taylor P, Radic Z, Marchot P. Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site, EMBO J. 2003;22:1-12.
16. Dvir H, Silman I, Harel M, Rosenberry TL, Sussman JL. Acetylcholinesterase: From 3D structure to function. Chem Biol Interact. 2010;187:10-22.
17. Stahura FL, Bajorath J. Virtual screening methods that complement HTS. Comb Chem High Throughput Screen. 2004 ;7:259-69.
18. Cheung J, Gary EN, Shiomi K, Rosenberry TL. Structures of human acetylcholinesterase bound to dihydrotanshinone I and territrem B show peripheral site flexibility. ACS Med Chem Lett. 2013;11:1091-6.
19. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001:46:3-26.
20. Grosdidier A. Conception d’un logiciel de docking et applications dans la recherche de nouvelles molécules actives. PhD Thesis : Joseph Fourier University, France; 2007.
21. Beri V, Wildman SA, Shiomi K, Al-Rashid Z, Cheung J, Rosenberry TL. The natural product dihydrotanshinone I provides a prototype for uncharged inhibitors that bind specifically to the acetylcholinesterase peripheral site with nanomolar affinity. Biochem. 2013; 52: 7486-99.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2021 Authors